Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...
UCalgary researchers to validate Mira Hormone Monitor
Bouchard needed to obtain clearance to examine the device prior to the company's submission for its approval for use in Canada.